News

The collaboration with WuXi Biologics will support the supply of Harbour's products for clinical trials under Investigational New Drug (IND) applications in China and worldwide. Harbour BioMed CEO

SNG001 was shown to be well tolerated in the two-part mid-stage trial, dubbed SG015, as per the interim safety data, said the UK-based respiratory drug discovery and development

The new facility will help the company to incorporate biologicals analytical and process development, as well as manufacturing units into one unit, enabling to maximize synergies and increase

Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of

AdoRx was founded in 2017 by leading healthcare investor Epidarex Capital and has assembled a group of highly experienced pharma industry veterans led by Pete Finan, former head

Since October 2008, the C1-Esterase inhibitor (C1-INH) has been approved in the US for routine prophylaxis against angioedema attacks in adolescents and adults with HAE. Cinryze’s latest approval

Hepatoblastoma is a rare type of primary liver cancer that affects young children and is often diagnosed in children under two. During the SIOPEL-6 clinical trial led by

Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug

Located in Boston’s booming biotech and pharmaceutical hub, PCI Synthesis offers its customers a wide range of services, including process research and early stage development as well as